SmartCGMS as an Environment for an Insulin-Pump Development with FDA-Accepted In-Silico Pre-Clinical Trials

Diabetes is a widespread civilization disease. It manifests with an elevated blood glucose level. In the long-term, elevated blood glucose level continuously damages organs. In the short-term, hypo- and hyperglycemia are acute complications. Insulin lowers blood glucose level by promoting its utilization. At basal rate, insulin pump delivers insulin to subcutaneous tissue to control blood glucose level. In addition, patient doses insulin boluses in accordance with estimated carbohydrate content of consumed meal. Control algorithm of the pump considers the boluses, when calculating the basal rate. In our previous work, we have proposed a parallel-architecture for the next-generation of glucose monitoring - SmartCGMS. It unifies the source-code base and the glucose-monitoring-and-control paradigm across real, simulated and prototyped devices. As the development continues, especially towards the pump-control algorithms, we face a problem of reducing the SmartCGMS requirements when considering a low-power hardware. In this paper, we present the modifications that lead to a reduced number of threads, while implementing the closed-loop feedback between a glucose sensor and insulin pump to conduct FDA accepted in-silico pre-clinical trials.